The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia

Clinical Cancer Research

Volumn 19, Issue 7, 2013, Pages 1795-1805

  Carol, Hernan ^a   Szymanska, Barbara ^a   Evans, Kathryn ^a   Boehm, Ingrid ^a   Houghton, Peter J ^b   Smith, Malcolm A ^c   Lock, Richard B ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CD19 ANTIGEN; DEXAMETHASONE; MESSENGER RNA; SAR 3419; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CANCER RECURRENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; LEUKEMIA REMISSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; INDUCTION CHEMOTHERAPY; MAYTANSINE; MICE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RNA, MESSENGER; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877100125     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3613     Document Type: Article

References (44)

1. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277-85.
2. Hunger SP, Raetz EA, Loh ML, Mullighan CG. Improving outcomes for high-risk ALL: translating new discoveries into clinical care. Pediatr Blood Cancer 2011;56:984-93.
3. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J Clin Oncol 2012;30:1663-9.
4. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29:551-65.
5. Li Y, Zhu Z. Monoclonal antibody-based therapeutics for leukemia. Expert Opin Biol Ther 2007;7:319-30. (Pubitemid 46383475)
6. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-87.
7. Harwood NE, Batista FD. New insights into the early molecular events underlying B cell activation. Immunity 2008;28:609-19. (Pubitemid 351636250)
8. Uckun F, Jaszcz W, Ambrus J, Fauci AS, Gajl-Peczalska K, Song CW, et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 1988;71:13-29. (Pubitemid 18050385)
9. Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, et al. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res 1993;53:1360-7. (Pubitemid 23097117)
10. Ek O, Gaynon P, Zeren T, Chelstrom LM, Myers DE, Uckun FM. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Leuk Lymphoma 1998;31:143-9. (Pubitemid 28428758)
11. Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Ahlgren LT, Chelstrom LM, et al. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995;267:886-91.
12. Multani PS, O'Day S, Nadler LM, Grossbard ML. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 1998;4:2599-604. (Pubitemid 28523485)
13. Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, et al. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer 2003;97:1471-80. (Pubitemid 36297777)
14. Morris JC, Waldmann TA. Antibody-based therapy of leukaemia. Expert Rev Mol Med 2009;11:e29.
15. Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 2009;113:4352-61.
16. Bernt KM, Prokop A, Huebener N, Gaedicke G, Wrasidlo W, Lode HN. Eradication of CD19+ leukemia by targeted calicheamicin. Bioconj Chem 2009;20:1587-94.
17. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res 2009;15:4038-45.
18. Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler M-E, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185-7.
19. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975;189:1002-5.
20. Cassady JM, Chan KK, Floss HG, Leistner E. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 2004;52:1-26. (Pubitemid 41685545)
21. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Accounts Chem Res 2008;41:98-107.
22. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 2010;9:2689-99.
23. Blackwell KL, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 30, 2012 (suppl; abstr LBA1).
24. Burris HA III, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
25. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
26. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528-37.
27. Lapusan S, Vidriales M, Thomas X, de Botton S, Vekhoss A, Tang R, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 2012;30:1121-31.
28. Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H, et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 2010;9:2700-13.
29. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011;17:6448-58.
30. Coiffier B, Ribrag V, Dupuis J, Tilly H, Haioun C, Morschhauser F, et al. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). ASCO Meeting Abstracts 2011;29:8017.
31. Younes A, Kim S, Romaguera J, Copeland A, Farial S, Kwak LW, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012;30:2776-82.
32. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002;99:4100-8. (Pubitemid 35332053)
33. Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004;103:3905-14. (Pubitemid 38596312)
34. Miranda HF, Puig MM, Prieto JC, Pinardi G. Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain. Pain 2006;121:22-8. (Pubitemid 43261628)
35. Nascimento JEB, Costa KA, Bertollo CM, Oliveira ACP, Rocha LTS, Souza ALS, et al. Pharmacological investigation of the nociceptive response and edema induced by venom of the scorpion Tityus serrulatus. Toxicon 2005;45:585-93. (Pubitemid 40381018)
36. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007;49:928-40. (Pubitemid 350022448)
37. Szymanska B, Carol H, Lock RB. Preclinical evaluation. In:Saha V, Kearns P, eds. New agents for the treatment of acute lymphoblastic leukemia. Springer: New York; 2011. p. 39-60.
38. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. Gene-Pattern 2.0. Nat Genet 2006;38:500-1.
39. Szymanska B, Wilczynska-Kalak U, Kang MH, Liem NLM, Carol H, Boehm I, et al. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One 2012;7:e33894.
40. Bezombes C, Fournie J-J, Laurent G. Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives. Mol Cancer Res 2011;9:1435-42.
41. Liu C, Lambert JM, Teicher BA, Blattler WA, O'Connor R. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood 1996;87:3892-8. (Pubitemid 26129619)
42. Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993;11:726-37. (Pubitemid 23105682)
43. Dinndorf P, Krailo M, Liu-Mares W, Frierdich S, Sondel P, Reaman G. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. J Immunother 2001;24:511-6. (Pubitemid 33104870)
44. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 2010;77:483-94.